

# Federica Perrone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9291443/publications.pdf>

Version: 2024-02-01

114  
papers

6,504  
citations

76322

40  
h-index

66906

78  
g-index

114  
all docs

114  
docs citations

114  
times ranked

11395  
citing authors

#	ARTICLE	IF	CITATIONS
1	High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 5630-5636.	1.6	605
2	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2009, 20, 84-90.	1.2	366
3	EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues. <i>American Journal of Pathology</i> , 2009, 174, 661-670.	3.8	301
4	Elevated Risk for MPNST in NF1 Microdeletion Patients. <i>American Journal of Human Genetics</i> , 2003, 72, 1288-1292.	6.2	271
5	BRAF alterations are associated with complex mutational profiles in malignant melanoma. <i>Oncogene</i> , 2004, 23, 5968-5977.	5.9	189
6	Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought. <i>Annals of Surgical Oncology</i> , 2013, 20, 4096-4102.	1.5	187
7	Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. <i>Oral Oncology</i> , 2009, 45, 574-578.	1.5	184
8	CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence. <i>Cancer</i> , 2013, 119, 3696-3702.	4.1	162
9	Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 6643-6651.	7.0	159
10	Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 74362-74379.	1.8	149
11	Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). <i>Oral Oncology</i> , 2009, 45, 986-990.	1.5	144
12	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , 2015, 26, 2092-2097.	1.2	137
13	Molecular and Biochemical Analyses of Platelet-Derived Growth Factor Receptor (PDGFR) B, PDGFRA, and KIT Receptors in Chordomas. <i>Clinical Cancer Research</i> , 2006, 12, 6920-6928.	7.0	135
14	Smoothed (SMO) receptor mutations dictate resistance to Vismodegib in basal cell carcinoma. <i>Molecular Oncology</i> , 2015, 9, 389-397.	4.6	131
15	miRNA Profiling in Colorectal Cancer Highlights miR-1 Involvement in MET-Dependent Proliferation. <i>Molecular Cancer Research</i> , 2012, 10, 504-515.	3.4	123
16	Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer. <i>British Journal of Cancer</i> , 2014, 110, 1001-1007.	6.4	118
17	Rb and TP53 Pathway Alterations in Sporadic and NF1-Related Malignant Peripheral Nerve Sheath Tumors. <i>Laboratory Investigation</i> , 2001, 81, 833-844.	3.7	117
18	TP53 Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 761-766.	1.6	104

#	ARTICLE	IF	CITATIONS
19	Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-“positive salivary gland cancers. <i>Head and Neck</i> , 2016, 38, 724-731.	2.0	104
20	Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. <i>Annals of Oncology</i> , 2012, 23, 1832-1837.	1.2	97
21	<i>p14</i> <sup>ARF</sup> , <i>p16</i> <sup>INK4a</sup> and <i>ras</i> gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. <i>International Journal of Cancer</i> , 2003, 105, 196-203.	5.1	89
22	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i> -Mutated Colorectal Cancer. <i>Cancer Discovery</i> , 2016, 6, 963-971.	9.4	85
23	Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. <i>Oncotarget</i> , 2016, 7, 4428-4441.	1.8	84
24	Evolutionary Action Score of <i>TP53</i> Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. <i>Cancer Research</i> , 2015, 75, 1205-1215.	0.9	78
25	miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma. <i>Oncotarget</i> , 2016, 7, 12731-12747.	1.8	77
26	Frequent Mutation and Nuclear Localization of $\beta$ -Catenin in Sertoli Cell Tumors of the Testis. <i>American Journal of Surgical Pathology</i> , 2014, 38, 66-71.	3.7	72
27	PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. <i>Neuro-Oncology</i> , 2009, 11, 725-736.	1.2	71
28	First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. <i>BJU International</i> , 2018, 121, 348-356.	2.5	70
29	<i>p15INK4b</i> , <i>p14ARF</i> , and <i>p16INK4a</i> inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. <i>Clinical Cancer Research</i> , 2003, 9, 4132-8.	7.0	69
30	Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. <i>Annals of Oncology</i> , 2014, 25, 404-408.	1.2	67
31	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. <i>European Journal of Cancer</i> , 2016, 69, 158-165.	2.8	66
32	Isolating <i>p16</i> -positive/HPV-negative Oropharyngeal Cancer. <i>American Journal of Surgical Pathology</i> , 2011, 35, 774-777.	3.7	65
33	Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. <i>Clinical Cancer Research</i> , 2016, 22, 3961-3970.	7.0	65
34	Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. <i>Lung Cancer</i> , 2012, 77, 507-514.	2.0	64
35	Intestinal type adenocarcinoma of the ethmoid sinus in wood and leather workers: A retrospective study of 153 cases. <i>Head and Neck</i> , 2011, 33, 535-542.	2.0	61
36	9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for <i>kit</i> and platelet-derived growth factor receptor $\pm$ gene alterations. <i>Cancer</i> , 2005, 104, 159-169.	4.1	56

#	ARTICLE	IF	CITATIONS
37	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O <sup>6</sup> -Methylguanine- $\alpha$ -DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1562-1573.	1.6	52
38	Autophagy acts as a safeguard mechanism against G-quadruplex ligand-mediated DNA damage. <i>Autophagy</i> , 2012, 8, 1185-1196.	9.1	51
39	FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma. <i>Oncologist</i> , 2014, 19, 845-850.	3.7	48
40	Integrative approach for prioritizing cancer genes in sporadic colon cancer. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 953-962.	2.8	47
41	Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. <i>Oncotarget</i> , 2016, 7, 3947-3965.	1.8	45
42	PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic $\beta$ -catenin and affects membrane distribution of $\beta$ -catenin/E-cadherin complexes in cancer cells. <i>Cellular Signalling</i> , 2008, 20, 872-883.	3.6	41
43	DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells. <i>Endocrine-Related Cancer</i> , 2013, 20, 23-37.	3.1	41
44	Oropharyngeal Squamous Cell Carcinoma Treated With Radiotherapy or Radiochemotherapy: Prognostic Role of TP53 and HPV Status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1053-1059.	0.8	39
45	TP53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. <i>Oral Oncology</i> , 2013, 49, 413-419.	1.5	39
46	Circulating Free DNA in a Screening Program for Early Colorectal Cancer Detection. <i>Tumori</i> , 2014, 100, 115-121.	1.1	39
47	Lack of SYT-SSX Fusion Transcripts in Malignant Peripheral Nerve Sheath Tumors on RT-PCR Analysis of 34 Archival Cases. <i>Laboratory Investigation</i> , 2002, 82, 609-618.	3.7	38
48	Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 231-236.	1.9	38
49	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 2858.	3.3	38
50	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. <i>Journal of Translational Medicine</i> , 2016, 14, 125.	4.4	36
51	Targeted Therapies: The Rare Cancer Paradigm. <i>Molecular Oncology</i> , 2010, 4, 19-37.	4.6	34
52	Phenotype-genotype correlation: Challenge of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. <i>Head and Neck</i> , 2006, 28, 909-915.	2.0	33
53	Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. <i>Annals of Oncology</i> , 2014, 25, 694-699.	1.2	33
54	p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. <i>Cancer</i> , 2007, 109, 2461-2465.	4.1	31

#	ARTICLE	IF	CITATIONS
55	Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed $\beta$ -catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 31-47.	2.8	31
56	Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. <i>European Journal of Cancer</i> , 2010, 46, 2837-2848.	2.8	30
57	Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma. <i>Cancers</i> , 2020, 12, 112.	3.7	30
58	$\beta$ -Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. <i>Molecular Oncology</i> , 2017, 11, 1495-1507.	4.6	28
59	Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens. <i>Cancer Biology and Therapy</i> , 2013, 14, 1098-1103.	3.4	27
60	<i>AKT1</i> and <i>BRAF</i> mutations in pediatric aggressive fibromatosis. <i>Cancer Medicine</i> , 2016, 5, 1204-1213.	2.8	27
61	Circulating free DNA in a screening program for early colorectal cancer detection. <i>Tumori</i> , 2014, 100, 115-21.	1.1	27
62	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. <i>Targeted Oncology</i> , 2014, 9, 155-162.	3.6	26
63	Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1560-1569.	1.1	26
64	Prognostic significance of the CaMBr1 antigen on breast carcinoma: Relevance of the type of recognised glycoconjugate. <i>European Journal of Cancer</i> , 1993, 29, 2113-2117.	2.8	24
65	Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. <i>Annals of Oncology</i> , 2011, 22, 1886-1893.	1.2	24
66	Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 678-682.	3.4	24
67	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. <i>Targeted Oncology</i> , 2016, 11, 337-343.	3.6	23
68	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. <i>Medical Oncology</i> , 2015, 32, 182.	2.5	22
69	Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 718-728.	1.1	22
70	Pulmonary adenocarcinoma with mucin production modulates phenotype according to common genetic traits: a reappraisal of mucinous adenocarcinoma and colloid adenocarcinoma. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 139-151.	3.0	22
71	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. <i>Investigational New Drugs</i> , 2016, 34, 236-242.	2.6	21
72	Challenging Lung Carcinoma with Coexistent $^{63}\text{Ni}$ /p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1500-1502.	1.1	20

#	ARTICLE	IF	CITATIONS
73	Bax Expression Is Predictive of Favorable Clinical Outcome in Chemonaive Advanced Gastric Cancer Patients Treated with Capecitabine, Oxaliplatin, and Irinotecan Regimen. <i>Translational Oncology</i> , 2012, 5, 155-159.	3.7	19
74	Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported <i>EWSR1</i> – <i>FEV3</i> translocation. <i>Histopathology</i> , 2014, 64, 1014-1026.	2.9	19
75	Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status. <i>PLoS ONE</i> , 2014, 9, e92147.	2.5	18
76	Novel intra-genic large deletions of <i>CTNNB1</i> gene identified in WT desmoid-type fibromatosis. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 495-503.	2.8	18
77	Neuroendocrine Small Cell Carcinoma of the Cervix Associated with Endocervical Adenocarcinoma. <i>Acta Cytologica</i> , 2007, 51, 589-593.	1.3	17
78	In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas. <i>Laboratory Investigation</i> , 2013, 93, 1232-1240.	3.7	17
79	Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. <i>European Journal of Cancer</i> , 2015, 51, 473-481.	2.8	17
80	Functional analysis and molecular modeling show a preserved wild-type activity of p53C238Y. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1467-1473.	4.1	16
81	Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework. <i>Oncotarget</i> , 2016, 7, 75503-75517.	1.8	16
82	Clear cell adenocarcinoma of the colon is a unique morphological variant of intestinal carcinoma: Case report with molecular analysis. <i>World Journal of Gastroenterology</i> , 2008, 14, 6575.	3.3	16
83	In situ hybridization detection methods for HPV16 E6/E7 mRNA in identifying transcriptionally active HPV infection of oropharyngeal carcinoma: an updating. <i>Human Pathology</i> , 2018, 74, 32-42.	2.0	15
84	Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma. <i>Modern Pathology</i> , 2020, 33, 217-227.	5.5	15
85	Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 651-662.	2.8	14
86	FHIT and p53 Status and Response to Platinum-Based Treatment in Advanced Non-Small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2008, 8, 342-348.	1.6	12
87	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2017, 16, e191-e198.	2.3	12
88	A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. <i>Oral Oncology</i> , 2019, 90, 94-101.	1.5	12
89	Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 922.	3.7	12
90	Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e403-e410.	1.9	11

#	ARTICLE	IF	CITATIONS
91	Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5817.	4.1	11
92	TP53 Mutations in Advanced Colorectal Cancer: The Dark Side of the Moon. <i>Oncology</i> , 2014, 86, 289-294.	1.9	10
93	Polymorphisms of Metabolizing Enzymes and Susceptibility to Ethmoid Intestinal-type Adenocarcinoma in Professionally Exposed Patients. <i>Translational Oncology</i> , 2009, 2, 84-88.	3.7	9
94	Identification of potentially druggable molecular alterations in skin adnexal malignancies. <i>Journal of Dermatology</i> , 2019, 46, 507-514.	1.2	9
95	Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 497-503.	2.8	8
96	Does Immunohistochemistry Affect Response to Therapy and Survival of Inoperable Non-Small Cell Lung Carcinoma Patients? A Survey of 145 Stage III-IV Consecutive Cases. <i>International Journal of Surgical Pathology</i> , 2014, 22, 136-148.	0.8	8
97	Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2015, 44, 734-745.	2.7	8
98	Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 435-443.	4.1	8
99	Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, e226-e228.	1.2	7
100	Role of BAX for outcome prediction in gastrointestinal malignancies. <i>Medical Oncology</i> , 2013, 30, 610.	2.5	7
101	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019, 18, 34-43.e6.	2.3	7
102	BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines. <i>Tumori</i> , 2014, 100, 315-20.	1.1	6
103	Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient. <i>Lung Cancer</i> , 2015, 87, 204-206.	2.0	5
104	Reproducibility between messenger RNA real-time polymerase chain reaction and messenger RNA in situ hybridization in oropharyngeal squamous cell carcinoma patients. <i>Human Pathology</i> , 2016, 47, 157-158.	2.0	4
105	Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. <i>Disease Markers</i> , 2017, 2017, 1-9.	1.3	4
106	Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers. <i>Tumori</i> , 2018, 104, 213-220.	1.1	4
107	Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma. <i>Oral Oncology</i> , 2016, 58, e4-e5.	1.5	3
108	Re: Oda et al. Frequent alteration of p16INK4a/p14ARF and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14ARF expression both correlate with poor prognosis. <i>J Pathol</i> 2005;207:410-421. <i>Journal of Pathology</i> , 2006, 209, 281-281.	4.5	2

#	ARTICLE	IF	CITATIONS
109	Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. <i>Clinical and Translational Oncology</i> , 2013, 15, 582-586.	2.4	2
110	Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 451-461.	2.8	2
111	Genetic Markers in Sporadic Tumors. , 2008, , 43-84.		2
112	Peritoneal Mesothelioma: Disease Biology and Patterns of Peritoneal Dissemination. , 2020, , 117-129.		2
113	TP53Mutations in Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2008, 358, 1194-1195.	27.0	1
114	Peritoneal Mesothelioma. <i>Updates in Surgery Series</i> , 2015, , 243-254.	0.1	0